A Phase 4 interventional study of clindamycin and benzoyl peroxide and Dapsone gel in Acne Vulgaris, sponsored by Stiefel, a GSK Company. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-05-30.
Sponsored by Stiefel, a GSK Company (part of GlaxoSmithKline) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing clindamycin in Acne Vulgaris — 1 open to participants now, 2 under way, none of them phase 3. Clindamycin · Acne Vulgaris.
Among the 34 studies testing clindamycin in Acne Vulgaris, this one is the 23rd largest by enrollment, is one of 8 that started in 2009, is one of 16 in phase 4, and was the 10th registered.
791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →1 of the 34 studies testing clindamycin in Acne Vulgaris is open now, in 1 country. Recruiting first, the newest first:
Centre for Human Drug Research, Netherlands · Sites in Netherlands
Ages 18–45 · Healthy volunteers
By country, each count listing its studies:
Clindamycin: first FDA approval 1970 (CLEOCIN HYDROCHLORIDE). What it is approved for, and how studies give it, is on its page →
Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 9 · Phase 4 16
First in 2005; this study’s year is marked. 8 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 53 is below the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 117 across the 34 interventional studies. Of the 30 that completed or were terminated, 19 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under Stiefel, a GSK Company, one of the names counted as GlaxoSmithKline. Under that name alone:
Stiefel, a GSK Company is the lead sponsor of 56 studies on the registry; none are open to participants now.
42 studies in Acne Vulgaris by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 42 finished, 24 (57%) have results posted.
Among the 42 studies in Acne Vulgaris by GlaxoSmithKline, this one is the 23rd largest by enrollment, is one of 13 that started in 2009, is one of 16 in phase 4, and was the 13th registered.
GlaxoSmithKline’s Acne Vulgaris studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing clindamycin in Acne Vulgaris, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 42 in Acne Vulgaris:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, half-face study. On 1 side of the face, the subject will apply 1 of the 2 test products, clindamycin and benzoyl peroxide or dapsone gel and the contra lateral side of the face will remain non-treated to serve as a control.
This is a single-blind (blinded expert grader), parallel group, randomized, half-face study being conducted at one clinical site. On 1 side of the face, the subject will apply 1 of the 2 test products, clindamycin and benzoyl peroxide or dapsone gel and the contra lateral side of the face will remain non-treated to serve as a control. Approximately 25-30 male and female healthy subjects without facial acne, aged 18 to 45, will be randomly assigned to each product.
The eligible subjects who qualify will be entered into a 2-week treatment phase. The first of application of the study medication will be supervised at the site, Monday through Friday of each week. Any additional applications should be applied by the subjects at home each evening and the times of application recorded on a diary card. Subjects will apply the study product at home on Saturdays and Sundays and record the times of application on a diary card.
A blinded expert grader will rate comparative product tolerance during the study before study product is applied.
Instrumentation measurements of TEWL will be utilized to evaluate product mildness.
Duplicate sebum samples will be taken from the left and right forehead areas and assessed.
Subject will complete questionnaires and all adverse events will be recorded.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Once-daily applications of clindamycin/BPO gel to the randomized side of the face either left or right.
Drug: clindamycin and benzoyl peroxide
Twice-daily applications of dapsone gel to one side of the face.
Drug: Dapsone gel
Drug pages: Clindamycin · Benzoyl Peroxide
Daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide
Also known as: Duac® gel
Twice-daily applications of dapsone gel
Also known as: ACZONE® (dapsone) Gel, 5%
Skin Erythema (Redness)
Assessment of erythema as part of an evaluation of tolerance of two treatments: clindamycin and benzoyl peroxide or dapsone gel. This was done by visual assessment by an independent blinded grader using the grading scale shown below. Grade Description 0 None 2 Mild erythema 4 Moderate confluent erythema 6 Marked erythema with some edema 8 Marked erythema, edema, possible erosion
Time frame: 2 Weeks
Skin Dryness
The amount of dryness on the left and right cheek of each panelist. The scale used to evaluate skin dryness is: Grade Description 0 None 2 Slight flaking 4 Moderate flaking/scaling 6 Marked scaling / slight fissuring 8 Severe scaling, fissuring Expert Grader assessments of dryness were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.
Time frame: Baseline, Day 1through Day 14
Transepidermal Water Loss (TEWL)
To assess skin moisture and hydration using transepidermal water loss (TEWL). These tables record the data obtained for each panelist at Baseline, and on Days 3, 7 and 14 or upon early termination of site(s), if applicable. Results are measured on a continuous scale.
Time frame: 2 Weeks
Sebum Measurements
To sample the skin surface, the sebum collector strips are applied to the skin sites for 10 seconds. Once removed, these samples will be immediately measured for the amount of sebum on the strip using the tape analyzer. The amount of sebum production was measured as the amount of sebum collected on a tape applied to the skin for 10 seconds and then converted to 1 of 10 incremental levels. Sebum production was measured in increments of 0 (minimum value) to 10 (maximum value). The higher the number, the greater amount of sebum produced.
Time frame: 2 weeks
Skin Hydration
Evaluation of Skin Hydration using electrical conductance measurements,on weekdays during 14 days of treatment. The value recorded which is expressed in units of microsiemens represents the AC conductance 2-3 seconds after placing the spring-loaded probe tip to the sample site.
Time frame: 2 weeks
Clinical research center. Subject recruitment occurred from July 16, 2009 to Aug. 11, 2009
| Milestone | Clindamycin and BPO Gel | Dapsone Gel |
|---|---|---|
| Started | 28 | 25 |
| Completed | 27 | 24 |
| Not completed | 1 | 1 |
| Withdrew: Did not qualify at day 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
Assessment of erythema as part of an evaluation of tolerance of two treatments: clindamycin and benzoyl peroxide or dapsone gel. This was done by visual assessment by an independent blinded grader using the grading scale shown below. Grade Description 0 None 2 Mild erythema 4 Moderate confluent erythema 6 Marked erythema with some edema 8 Marked erythema, edema, possible erosion
| Units on a scale | Clindamycin and BPO Gel | Dapsone Gel |
|---|---|---|
| Baseline | 1.06 ± 0.79 | 1.18 ± 0.63 |
| Day 1 | 1.26 ± .76 | 1.34 ± .81 |
| Day 2 | 1.55 ± .84 | 1.33 ± .85 |
| Day 3 | 1.32 ± .63 | 1.50 ± .59 |
| Day 6 | 1.30 ± .75 | 1.65 ± .92 |
| Day 7 | 1.64 ± 1.02 | 1.53 ± .82 |
| Day 8 | 1.80 ± .80 | 1.60 ± .93 |
| Day 9 | 1.67 ± .95 | 1.45 ± .89 |
| Day 10 | 1.81 ± .89 | 1.85 ± 1.13 |
| Day 13 | 1.52 ± 1.20 | 1.65 ± 1.05 |
| Day 14 | 2.10 ± 1.09 | 1.90 ± 1.15 |
To assess skin moisture and hydration using transepidermal water loss (TEWL). These tables record the data obtained for each panelist at Baseline, and on Days 3, 7 and 14 or upon early termination of site(s), if applicable. Results are measured on a continuous scale.
| TEWL rates (gm/m2/hr) | Clindamycin and BPO Gel | Dapsone Gel |
|---|---|---|
| Baseline | 10.29 ± 3.06 | 10.4 ± 2.93 |
| Day 3 | 12.34 ± 4.80 | 11.21 ± 3.26 |
| Day 7 | 14.39 ± 3.73 | 11.53 ± 3.09 |
| Day 14 | 13.88 ± 3.70 | 11.26 ± 3.08 |
The amount of dryness on the left and right cheek of each panelist. The scale used to evaluate skin dryness is: Grade Description 0 None 2 Slight flaking 4 Moderate flaking/scaling 6 Marked scaling / slight fissuring 8 Severe scaling, fissuring Expert Grader assessments of dryness were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.
| Units on a scale | Clindamycin and BPO Gel | Dapsone Gel |
|---|---|---|
| Baseline | 0.11 ± 0.32 | 0.12 ± 0.33 |
| Day 1 | 0.04 ± 0.05 | 0.28 ± 0.71 |
| Day 2 | 0.10 ± 0.26 | 0.23 ± 0.57 |
| Day 3 | 0.16 ± 0.32 | 0.48 ± 0.81 |
| Day 6 | 0.27 ± 0.79 | 0.37 ± 0.64 |
| Day 7 | 0.21 ± 0.45 | 0.23 ± 0.47 |
| Day 8 | 0.54 ± 1.03 | 0.17 ± 0.35 |
| Day 9 | 0.5 ± 1.04 | 0.10 ± 0.20 |
| Day 10 | 0.57 ± 0.91 | 0.15 ± 0.44 |
| Day 13 | 0.57 ± 1.24 | 0.17 ± 0.45 |
| Day 14 | 0.55 ± 1.11 | 0.12 ± 0.28 |
To sample the skin surface, the sebum collector strips are applied to the skin sites for 10 seconds. Once removed, these samples will be immediately measured for the amount of sebum on the strip using the tape analyzer. The amount of sebum production was measured as the amount of sebum collected on a tape applied to the skin for 10 seconds and then converted to 1 of 10 incremental levels. Sebum production was measured in increments of 0 (minimum value) to 10 (maximum value). The higher the number, the greater amount of sebum produced.
| units on a scale | Clindamycin and BPO Gel | Dapsone Gel |
|---|---|---|
| Baseline | 1.72 ± 1.31 | 2.18 ± 1.73 |
| Day 3 | 1.52 ± 1.01 | 1.72 ± 1.11 |
| Day 7 | 2.65 ± 2.05 | 3.33 ± 2.43 |
| Day 14 | 2.35 ± 2.01 | 2.38 ± 1.67 |
Evaluation of Skin Hydration using electrical conductance measurements,on weekdays during 14 days of treatment. The value recorded which is expressed in units of microsiemens represents the AC conductance 2-3 seconds after placing the spring-loaded probe tip to the sample site.
| Microsiemens | Clindamycin and BPO Gel | Dapsone Gel |
|---|---|---|
| Baseline | 499.51 ± 124.27 | 448.31 ± 149.26 |
| 4 hours post 1st treatment | 430.38 ± 156.71 | 404.68 ± 170.45 |
| Day 3 | 614.73 ± 144.64 | 511.63 ± 163.97 |
| Day 7 | 460.65 ± 169.03 | 456.73 ± 173.07 |
| Day 14 | 477.80 ± 173.40 | 471.13 ± 194.77 |
Collected over 14 days.. Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Clindamycin and BPO Gel | — | 0/27 (0%) | 2/27 (7.4%) |
| Dapsone Gel | — | 0/25 (0%) | 2/25 (8%) |
| Event | Clindamycin and BPO Gel | Dapsone Gel |
|---|---|---|
| HeadacheNervous system disorders | 1/27 | 1/25 |
| InfectionInfections and infestations | 1/27 | 1/25 |
| Age, Categorical(Participants) | Clindamycin and BPO Gel | Dapsone Gel | Total |
|---|---|---|---|
| <=18 years | 2 | 1 | 3 |
| Between 18 and 65 years | 26 | 24 | 50 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Clindamycin and BPO Gel | Dapsone Gel | Total |
|---|---|---|---|
| Female | 21 | 22 | 43 |
| Male | 7 | 3 | 10 |
| Region of Enrollment(participants) | Clindamycin and BPO Gel | Dapsone Gel | Total |
|---|---|---|---|
| United States | 28 | 25 | 53 |
The record gives a start of Jul 2009, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2012, 2 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Clindamycin · Benzoyl Peroxide